In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancer-related ...

Compared to placebo, high-dose recombinant human erythropoietin within 2 days of life does not improve neurodevelopmental outcomes for preterm infants.

Originally blood tests were introduced for medical reasons and for limiting misuse of recombinant human erythropoietin (rHuEPO). In this way it became possible to prevent athletes with haematocrit ...

Routine administration of recombinant erythropoietin to patients on hemodialysis has greatly facilitated the management of chronic-kidney-disease-induced anemia. However, this glycoprotein hormone ...

Indeed, several of Amgen's claims contain language that the EPO product can not be “isolated from human urine” or that the vertebrate cells produce ”in excess of 100 U of erythropoietin per ...

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...

Discover the commercial and brand names of the generic drug Erythropoietin. This indispensable guide is essential for healthcare professionals, patients, caregivers, and anyone seeking to ...

The aim of the present study was to examine whether the variability in the increase in total haemoglobin mass after training at moderate altitude could be predicted by the erythropoietin response ...